Recent Research and Knowledge on Treatment for Hepatitis B
10.4167/jbv.2020.50.3.175
- Author:
Hye-won LEE
1
;
Yongwook CHOI
;
Yong Kwang PARK
Author Information
1. Division of Viral Disease Research, Center for Infectious Disease Research, Korea National Institute of Health, Chungbuk 28159, Republic of Korea
- Publication Type:MINI REVIEW ARTICLE
- From:Journal of Bacteriology and Virology
2020;50(3):175-180
- CountryRepublic of Korea
- Language:English
-
Abstract:
Hepatitis B virus (HBV) infection is a major public health problem, with some 250 million people currently at high risk of developing chronic liver diseases. The current antiviral treatment for chronic hepatitis B (CHB) is effective in controlling viral replication but fails to achieve a complete cure. Since the identification of sodium taurocholate cotransport polypeptide (NTCP) as an HBV receptor, anti-HBV drugs targeting viral entry, capsid assembly, cccDNA, transcription, and secretion have been developed. In this paper, the potential inhibitors in various steps of the HBV life cycle are summarized.
